Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Exp Neurol. 2014 Dec 24;265:8–21. doi: 10.1016/j.expneurol.2014.12.015

Fig. 5.

Fig. 5

Induction of spinal cord disease signs upon i.th. application of recombinant anti-AQP4 ABs. A: I.th. injections of recombinant antibody against AQP4 (rABAQP4) caused signs of myelopathy. Animals treated with half the amount of rABAQP4 (rABAQP4–50%) showed significantly lower disease scores over time corroborating the dose–response relation observed with patient IgG antibodies. Recombinant control ABs (rABcontr1, rABcontr2) had no effect (left: scores over the entire time course, right: mean group score values *p < 0.05; ***p < 0.001; color-coded asterisks indicate comparisons of treatment groups). B: Progressive deficits in RotaRod testing accumulated over time following 5, 10, or 15 i.th. applications of anti-AQP4 rABs (abscissa: time on rod, relative to individual baseline values normalized at 1.0; *p < 0.05; **p < 0.01; as compared to baseline values). The individual AB preparations are color-coded (for interpretation of the references to color in this fiure legend, the reader is referred to the web version of the article).